Clinical Guides
Infertility
A source-grounded guide to couple-centred infertility assessment, cause-directed management, assisted reproduction and India-specific regulation, prepared for mandatory clinical review.
MedNext Academy | 14 min read
Infertility
A source-grounded guide to couple-centred infertility assessment, cause-directed management, assisted reproduction and India-specific regulation, prepared for mandatory clinical review.
Summary
Infertility is failure to achieve pregnancy after 12 months or more of regular unprotected sexual intercourse. It may be primary, when no previous pregnancy has occurred, or secondary, after a previous conception regardless of outcome. The definition provides a service threshold, not a reason to wait when time matters. Evaluation may begin after six months when the female partner is 35 or older, more immediately over 40, and without delay when there is amenorrhoea, markedly irregular cycles, suspected tubal or uterine disease, endometriosis, sexual dysfunction, known male subfertility, prior gonadotoxic treatment or another condition that impairs reproduction.
Assessment should include both partners concurrently when partners contribute sperm and oocytes. A systematic pathway evaluates intercourse and sexual function, ovulation, uterine and tubal anatomy, and semen. Tests are selected from history and examination; indiscriminate hormone panels, routine laparoscopy and ovarian-reserve testing used as a general fertility screen add cost without necessarily answering the clinical question. Unexplained infertility is a diagnosis after normal history and examination, presumptive ovulation, tubal patency and semen parameters, not a label applied before completing basic evaluation.
Management progresses from information, fertility optimisation and cause-specific treatment to ovulation induction, surgery, intrauterine insemination or in vitro fertilisation when appropriate. Age, duration, prognosis, cost, treatment burden, multiple-pregnancy risk and patient preference shape the pace. Psychosocial support is part of care. In India, ART services operate within the Assisted Reproductive Technology (Regulation) Act and associated rules and regulations. This educational draft is not an individual treatment plan and remains awaiting specialist review.
How Common Is It?
WHO estimates that about one in six people of reproductive age experience infertility at some point in life. This is a global lifetime estimate, not an India-specific clinic rate and not a prediction for an individual couple. Prevalence estimates vary with definition, age structure, duration of follow-up, whether people are attempting pregnancy, and whether primary and secondary infertility are combined. Clinic populations overrepresent those able and willing to seek care, while household surveys may miss sexual dysfunction, same-sex couples, single people seeking fertility care and those who have stopped trying.
Infertility has consequences beyond the absence of pregnancy. Repeated cycles of hope and loss can cause anxiety, low mood, grief, relationship strain, sexual difficulty, stigma and social isolation. In settings where parenthood has strong family or economic meaning, women may be blamed even when male factors contribute. Costs accumulate from travel, repeated tests, time away from work and treatments paid largely out of pocket. WHO’s 2025 guideline therefore places preferences, affordability, psychosocial support and equitable access alongside biomedical efficacy.
Age is central to prognosis but should be communicated without blame. Female fecundity declines with age, particularly in the later reproductive years, while male reproductive ageing and medical factors also matter. The probability of spontaneous conception changes with both partners’ factors and duration of infertility. This guide avoids unsupported percentages for male, female, combined and unexplained causes because distributions differ by population and referral setting. The robust lesson is to assess the couple or reproductive partners together, use time efficiently and not assume the person presenting first is the cause.
Risk Factors
Female-factor risks include advancing reproductive age, irregular or absent ovulation, polycystic ovary syndrome, diminished ovarian reserve, endometriosis, prior pelvic inflammatory disease, genital tuberculosis, ectopic pregnancy, pelvic or tubal surgery, uterine cavity disease, fibroids that distort the cavity, congenital anomalies and gonadotoxic chemotherapy or radiotherapy. Severe undernutrition, obesity and endocrine disorders may disturb ovulation. A previous pregnancy does not exclude later tubal, ovulatory, uterine or age-related infertility.
Male-factor risks include undescended testes, torsion, orchitis, genital trauma or surgery, varicocele with abnormal semen, obstruction, genetic or endocrine disorders, erectile or ejaculatory dysfunction, systemic illness, heat or occupational exposures, chemotherapy and radiotherapy. Exogenous testosterone and anabolic steroids can suppress spermatogenesis and must be asked about directly. Medicines, tobacco, alcohol and recreational substances require a non-judgemental review for both partners. A single risk factor does not prove causation, and normal sexual function does not guarantee normal semen parameters.
Untreated sexually transmitted infections can impair fertility through tubal or male-tract damage. WHO recommends routine information about this preventable risk and prompt care for symptoms. Lifestyle advice should be realistic: stop tobacco, support a balanced diet and physical activity, address unhealthy weight and reduce harmful alcohol use, while avoiding promises that lifestyle change alone will overcome fixed tubal obstruction, severe male factor or age-related decline.
Earlier evaluation is justified when any high-risk feature exists, when the female partner is 35 or older, or when preservation before gonadotoxic treatment is being considered. Reproductive coercion, violence, stigma and financial vulnerability also affect safety and consent. Ask whose pregnancy goal is being pursued and whether both partners can speak freely.
Diagnosis
Infertility evaluation should be systematic, expeditious and least invasive first. Confirm the duration and pattern of exposure to pregnancy, then investigate ovulation, the reproductive tract and semen in parallel. The aim is a working diagnosis and prognosis, not the largest possible panel.
History
Take both partners’ reproductive histories separately where privacy helps. Ask duration of attempts, intercourse frequency and timing, contraception cessation, prior pregnancies and outcomes, menstrual regularity, amenorrhoea, dysmenorrhoea, pelvic pain, discharge, STI or tuberculosis exposure, pelvic surgery and prior fertility treatment. Review sexual function, dyspareunia, vaginismus, erectile or ejaculatory difficulty and use of lubricants. Record medical, surgical, developmental, medication, supplement, tobacco, alcohol, substance, occupation, family and gonadotoxic exposure histories. Ask about pregnancy goals, genetic concerns, treatment limits, cost and emotional impact.
Examination
Examination is targeted. Measure blood pressure and assess BMI when relevant. In the female partner, look for thyroid disease, hyperandrogenism, galactorrhoea, undernutrition or systemic illness; abdominal or pelvic examination is guided by pain, bleeding, mass, infection or suspected anatomy. In the male partner, examine virilisation, gynaecomastia, testes, epididymides, vas deferens and clinically suspected varicocele when indicated. Respect consent, gender identity and trauma; a complete pelvic examination is not obligatory for every person at the first visit.
Investigations
Obtain at least one semen analysis early using a standard laboratory; abnormal results require appropriately timed repetition and male evaluation. WHO 2025 suggests repeating abnormal semen parameters after at least 11 weeks and not routinely repeating a fully normal analysis. Regular cycles often support ovulation; if confirmation is needed, measure progesterone about seven days before the expected period rather than automatically on cycle day 21. Hormonal tests are cause-directed. Assess tubal patency with HSG or HyCoSy when indicated. Ultrasound evaluates pelvic anatomy; SIS or hysteroscopy is selected for cavity questions. Ovarian-reserve tests help predict response in selected treatment contexts but are not a binary natural-fertility test.
Differential Diagnosis
Classify contributors without forcing every couple into a single category. Ovulatory infertility includes PCOS, hypothalamic amenorrhoea, hyperprolactinaemia, thyroid disease, primary ovarian insufficiency and age-related decline. Tubal or peritoneal causes include previous pelvic inflammatory disease, genital tuberculosis, endometriosis, adhesions, prior ectopic pregnancy and pelvic surgery. Uterine or cervical contributors include cavity-distorting fibroids, polyps, adhesions, congenital anomalies and selected cervical problems. Endometriosis can affect fertility through inflammation, anatomy and ovarian reserve even when imaging is normal.
Male infertility may reflect impaired production, obstruction, endocrine or genetic disease, varicocele, infection, sexual dysfunction, medicines or gonadotoxic exposure. Semen results vary and do not by themselves identify the cause. Azoospermia requires distinction between obstruction and impaired spermatogenesis and may need hormonal, genetic and imaging assessment. Do not expose only the female partner to invasive testing while deferring a straightforward semen analysis.
Coital and sexual factors include infrequent intercourse, misunderstanding of the fertile window, erectile dysfunction, anejaculation, retrograde ejaculation, dyspareunia and vaginismus. Pregnancy loss is distinct from failure to conceive, though both can coexist. Apparent infertility may also reflect recent contraception cessation, breastfeeding-related anovulation or insufficient duration of exposure.
WHO defines unexplained infertility only after 12 months of exposure, normal history and examination in both partners, presumptive ovulation and patent tubes in the female partner, and semen parameters within reference ranges. It is a diagnosis of the current limits of testing, not proof that no biological factor exists. Prognosis then depends on age, duration and previous pregnancy as well as test results.
Management
Begin with a shared formulation: identified factors, prognosis, what remains uncertain, and the least burdensome effective next step. Explain the fertile window without prescribing intercourse in a way that worsens distress. Offer smoking cessation, balanced nutrition, physical activity, healthy weight support, STI prevention, medication review and preconception folate according to current local guidance. Treat sexual dysfunction and provide psychosocial support. Do not recommend unregulated supplements, traditional remedies or add-on procedures with unproven benefit.
Cause-directed management may include treatment of thyroid or prolactin disorders, ovulation induction, selected endometriosis or uterine surgery, tubal intervention, treatment of clinical varicocele with abnormal semen, or sperm retrieval. For PCOS-related anovulation, WHO 2025 suggests letrozole over clomiphene or metformin where legally and clinically permitted. These medicines require a confirmed diagnosis and monitoring plan because multiple pregnancy and ovarian response matter. Severe tubal disease, major male factor, advancing age or failed simpler treatment may justify earlier IVF or ICSI.
For unexplained infertility, WHO suggests a stepwise approach. Initial expectant management for an appropriate prognosis includes lifestyle and fertile-window advice, typically for a defined period. If unsuccessful, stimulated IUI with clomiphene or letrozole can be considered; gonadotrophin stimulation carries greater multiple-pregnancy and monitoring burden. IVF follows unsuccessful stimulated IUI in suitable couples. WHO recommends conventional IVF rather than automatically adding ICSI when unexplained infertility reaches IVF, unless a separate indication exists.
Every plan needs time limits and review criteria. Discuss live-birth outcomes rather than only biochemical pregnancy, cumulative cost, cancellation, multiple gestation, OHSS, procedure risks and emotional burden. Respect a decision to pause, stop, pursue adoption where available or live without treatment.
Prescribing Information
Fertility medicines should be prescribed by clinicians able to confirm the indication, monitor response and manage complications. This guide intentionally provides no self-treatment doses or cycle schedule. Before ovulation induction, establish pregnancy status, the cause of anovulation, tubal considerations, semen findings, contraindications and a plan for ultrasound or laboratory monitoring. Verify Indian authorisation and whether a use is off label. Do not dispense repeated cycles without assessing ovulation, follicle number, endometrium, adverse effects and cumulative exposure.
Letrozole is a first option in WHO’s 2025 PCOS infertility recommendation where its use is legally permitted. Clomiphene is an alternative or part of a different pathway; both can produce multiple follicular development. Gonadotrophins require specialist low-dose protocols and close monitoring because multifollicular response, multiple pregnancy and ovarian hyperstimulation can occur. Human chorionic gonadotrophin triggers and luteal support are protocol-specific. Cancel or modify an unsafe response rather than pursuing conception at any cost.
Cabergoline may be preferred over bromocriptine for hyperprolactinaemic ovulatory infertility in WHO guidance, but the diagnosis, pituitary assessment and pregnancy plan come first. Exogenous testosterone is not a treatment for a man seeking fertility because it suppresses gonadotrophins and spermatogenesis. Antioxidant supplements should not be presented as proven male-infertility therapy; WHO made no recommendation for or against them because evidence is insufficient.
IVF medicines and procedures carry risks including OHSS, torsion, bleeding, infection, anaesthesia complications, thrombosis and multiple pregnancy. Give written emergency advice and clinic contact details. Check all medicines and supplements for pregnancy safety once conception occurs. Prescribing records should include indication, consent, monitoring, response, cancelled cycles, complications and referral thresholds.
When to Refer
Refer early to a fertility specialist when the female partner is 35 or older after six months of attempts, more immediately over 40, or without delay for amenorrhoea, severe cycle irregularity, known tubal disease, moderate or severe endometriosis, uterine cavity pathology, diminished ovarian reserve risk, previous gonadotoxic treatment or a condition requiring fertility preservation. Referral is also appropriate when basic evaluation is complete but no pregnancy occurs within the agreed timeframe or when treatment exceeds primary-care competence.
Refer the male partner to reproductive urology or andrology for azoospermia, severe oligozoospermia, persistent abnormal semen, small or absent testes, absent vas deferens, endocrine abnormalities, a testicular mass, significant varicocele with abnormal semen, ejaculatory dysfunction or suspected genetic disease. A palpable testicular mass is urgent and fertility preservation should be coordinated without delaying cancer care. Abnormal semen should not be managed solely by sending the female partner for IVF.
Genetic counselling is indicated for suspected chromosomal or monogenic disease, recurrent relevant family history, congenital absence of the vas deferens, severe sperm-production defects, premature ovarian insufficiency and consideration of preimplantation genetic testing. Refer to appropriate infection or tuberculosis services when indicated, avoiding empirical anti-tuberculous treatment without diagnosis.
Urgent assessment is needed for severe pain, abdominal distension, breathlessness, reduced urine output, rapid weight gain, collapse or thrombosis symptoms during ovarian stimulation because of possible OHSS or another acute complication. A positive pregnancy after treatment still needs location and viability assessment according to risk. Referral to mental-health support should be offered for severe distress, depression, self-harm thoughts, relationship violence or treatment-related trauma.
Red Flags
Infertility itself is rarely an emergency, but its causes and treatments can be. A testicular mass, acute testicular pain, virilisation, rapid-onset androgen excess, a pelvic mass, postcoital or persistent intermenstrual bleeding, unexplained weight loss, galactorrhoea with neurological symptoms, or severe pelvic pain warrants expedited assessment. Amenorrhoea with headache or visual change may signal pituitary disease. A positive pregnancy test with pain, bleeding, syncope or shoulder-tip pain requires ectopic-pregnancy evaluation.
During ovarian stimulation, rapidly increasing abdominal distension, severe pain, persistent vomiting, breathlessness, oliguria, rapid weight gain, leg swelling, chest pain, neurological symptoms or collapse suggests severe ovarian hyperstimulation, torsion, haemorrhage or thrombosis. Stop routine treatment communication and use the clinic’s emergency pathway. After egg retrieval or embryo transfer, fever, heavy bleeding or worsening pain is not simply expected discomfort.
Psychosocial red flags include severe depression, suicidal thoughts, intimate-partner violence, reproductive coercion, pressure to use donor gametes, financial exploitation or inability to give free consent. Interview separately when needed and ensure that consent can be withdrawn within the applicable legal and procedural framework. Treatment success statistics must not be manipulated to create urgency or sell add-ons.
Legal and ethical warning signs in India include an unregistered ART clinic or bank, absence of written informed consent, refusal to explain cost and risk, sex-selection offers, undisclosed gamete sourcing, poor recordkeeping or promises of guaranteed success. The ART Act requires registered services, counselling and consent and prohibits sex selection. Suspected misconduct requires senior clinical, regulatory or legal escalation, not private negotiation alone.
Indian Clinical Context
Infertility care in India ranges from primary evaluation to high-complexity ART, with major differences in cost, laboratory quality, travel and access to trained specialists. Genital tuberculosis is an important cause in selected patients, but symptoms and local prevalence do not justify empirical treatment: pursue appropriate gynaecological and tuberculosis evaluation. Do not convert global lifetime prevalence into an India-specific statistic without a current representative source. The 2025 WHO guideline provides clinical recommendations intended for national adaptation, not a claim that every test or treatment is publicly available.
The Assisted Reproductive Technology (Regulation) Act, 2021 regulates ART clinics and banks. It requires registration, professional counselling about implications, chances of success, advantages, disadvantages, costs, side effects and multiple-pregnancy risk, and written informed consent. It also provides confidentiality duties and prohibits sex selection. Patients considering ART should verify the clinic’s current registration and receive itemised information about tests, medicines, procedures, storage, cancellation, refunds and follow-up. The Act’s legal definitions and eligibility provisions must be read with current rules, regulations and amendments; this clinical guide is not legal advice.
Public-sector access and insurance coverage vary. A staged evaluation can reduce waste: assess both partners, obtain semen early, confirm ovulation only when needed, and choose tubal or cavity tests from the clinical question. Repeated proprietary panels and unproven add-ons can consume resources without improving live-birth probability. Discuss the cost per full treatment pathway, not only the advertised first visit or embryo-transfer price.
Use inclusive, respectful language while explaining the legal terms that govern a particular service. Family pressure, stigma and gendered blame are common safety concerns. Counselling should preserve privacy and the individual right to stop. Referral for adoption information or psychosocial support should be offered neutrally, not as evidence that treatment has failed morally.
NMC Competency Mapping
The NMC CBME Curriculum 2024 assigns four Obstetrics and Gynaecology competencies to infertility. OG28.1 requires discussion of common causes, pathogenesis, clinical features, differential diagnosis, investigations and principles of management, including tubal patency, ovulation induction and assisted reproductive techniques. OG28.2 addresses assessment and restoration of tubal patency. OG28.3 covers principles of ovulation induction. OG28.4 requires enumeration of assisted reproductive techniques. OG28.1 and OG28.3 are core; OG28.2 and OG28.4 are listed as non-core knowledge outcomes.
At Know and Know How level, learners should define primary and secondary infertility, know when to start earlier evaluation, assess both partners, interpret menstrual and semen histories, choose ovulation and tubal tests, and distinguish male, ovulatory, tubal, uterine, endometriosis-related and unexplained infertility. They should understand that ovarian reserve predicts response imperfectly and that normal semen reference ranges do not guarantee fertility.
Learners should explain expectant management, cause-directed therapy, ovulation induction, IUI, IVF, ICSI, gamete or embryo cryopreservation and major risks. They should recognise OHSS and ectopic pregnancy, counsel about multiple gestation and know that ART in India is regulated. Demonstrating respectful history-taking and shared decision-making is more clinically meaningful than recalling treatment abbreviations alone.
Integration spans reproductive physiology, endocrinology, genetics, andrology, radiology, microbiology, pharmacology, ethics, communication and law. A learner may observe an IVF laboratory, but neither observation nor this guide authorises independent prescribing or procedures. Formal mapping should retain the exact OG28.1 to OG28.4 wording and use the institution’s current logbook.
Key Exam Pearls for NEET PG
Infertility is failure to achieve pregnancy after at least 12 months of regular unprotected intercourse. Begin evaluation at 12 months when the female partner is under 35, at six months from 35 onward, and more immediately over 40 or when a known cause exists. Primary means no previous pregnancy; secondary follows any previous conception. Evaluate both partners together.
Core work-up covers ovulation, tubal and uterine anatomy, and semen. Obtain semen analysis early. WHO 2025 suggests repeating an abnormal analysis after at least 11 weeks and not repeating a fully normal analysis routinely. In a regular cycle, ovulation is often presumptive; when progesterone is used, time it about seven days before the expected period, not rigidly on day 21. HSG or HyCoSy assesses tubal patency. Ovarian reserve tests predict stimulation response better than natural conception and should not be used as a simple fertility verdict.
Unexplained infertility requires normal histories and examinations, presumptive ovulation, patent tubes and semen within reference ranges after 12 months. WHO’s pathway is expectant management first for suitable couples, then stimulated IUI, then IVF if unsuccessful. Do not add ICSI automatically to IVF without a male or fertilisation indication.
For PCOS anovulatory infertility, WHO prefers letrozole where permitted. Gonadotrophins require monitoring because of multiple pregnancy and OHSS. Severe pain, distension, breathlessness, oliguria or thrombosis symptoms during stimulation is urgent. Indian ART exam answers should mention registered clinics, counselling, written informed consent, confidentiality and the prohibition of sex selection under the ART Act.
Frequently Asked Questions
When should a couple seek assessment for infertility?
Seek assessment after 12 months of regular unprotected intercourse when the female partner is under 35, after six months from age 35, and more immediately over 40. Do not wait when cycles are absent or markedly irregular, tubal disease or endometriosis is suspected, semen or sexual problems are known, or gonadotoxic treatment is planned.
Why should both partners be evaluated at the same time?
Male, female and combined contributors are all possible, and delaying semen analysis can lead to unnecessary invasive testing of the female partner. Parallel history, examination when indicated, semen assessment, ovulation review and tubal or uterine evaluation shorten the pathway and allow treatment to address the actual combination of factors rather than assigning blame.
Does a low AMH result prove natural pregnancy is impossible?
No. Anti-Müllerian hormone is mainly useful for estimating ovarian response to stimulation in a defined clinical context. It does not directly measure egg quality and cannot provide a binary verdict on spontaneous conception. Age, ovulation, tubes, semen, duration of infertility and prior pregnancy all matter. Results require interpretation with the assay, ultrasound and treatment goal.
What does unexplained infertility mean after a normal work-up?
It means current standard assessment has not identified a cause after at least 12 months: both histories and examinations are normal, ovulation is presumed, tubes are patent and semen parameters are within reference ranges. It does not mean the difficulty is imaginary. Prognosis and treatment still depend on age, duration, preferences and previous pregnancy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic